VAPE protocol

chemotherapy protocol consisting of above compounds; used in the treatment of advanced small cell lung cancer (SCLC)

Networked: 0 relevant articles (0 outcomes, 0 trials/studies)

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - VAPE protocol
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - VAPE protocol
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - VAPE protocol
Organic Chemicals: 133
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Tetrahydronaphthalenes: 1
      - Podophyllotoxin: 562
        Etoposide: 10706
        VAPE protocol
  - Naphthacenes
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        Doxorubicin: 35390
        VAPE protocol
Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        Doxorubicin: 35390
        VAPE protocol
  - Glucosides: 639
    - Etoposide: 10706
      - VAPE protocol
Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Indole Alkaloids: 200
    - Secologanin Tryptamine Alkaloids: 81
      - Vinca Alkaloids: 463
        Vincristine: 9251
        VAPE protocol
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Indole Alkaloids: 200
        Secologanin Tryptamine Alkaloids: 81
        Vinca Alkaloids: 463
        Vincristine: 9251
        VAPE protocol
    - Indolizines: 3
      - Indolizidines: 2
        Indole Alkaloids: 200
        Secologanin Tryptamine Alkaloids: 81
        Vinca Alkaloids: 463
        Vincristine: 9251
        VAPE protocol